The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK PLC closed 25.53% below its 52-week high of £18.24, which the company reached on May 16th.

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...